AI interpretation based on checked source excerpts. Issuer assertions and evidence limitations remain explicit.
Policy quality-scores-2: six equally weighted categories. The overall score requires full coverage. Missing inputs are not zero. Qualitative grades are sourced interpretations, not probabilities. 4/6 · 18/10/2026
Moat56
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
structural advantage · 3/4 · Exclusive licensed rights and realized intellectual-property payments and royalties demonstrate monetizable intangible assets. Product-specific competitive superiority remains unestablished.
durability · 2/4 · Royalties and product revenues persist and grow across disclosed periods, but remaining exclusivity is unspecified and management acknowledges preparation for loss of exclusivity. Pipeline forecasts cannot establish replacement durability.
customer dependency · 2/4 · Multiyear commercial sales and recurring royalties indirectly indicate continuing demand. They do not establish patient dependence, prescription persistence or switching friction.
erosion resilience · 2/4 · Reported growth outside Jakafi supports some diversification. Protection against exclusivity loss, equivalent therapies and pricing pressure remains unproven; the disclosed risks are possibilities rather than evidence of realized displacement.
Pricing power38
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
realized pricing · 1/4 · Actual sales allowances establish substantial reductions from gross sales, including $1.058 billion of current-period rebates and chargebacks in first-half 2026. Prior-period reversals also affect realization. This supports constrained pricing, while no price-volume bridge establishes sustained net price increases or a realized price decline over time.
retention · 2/4 · Growing multiyear sales and recurring OLUMIANT royalties indirectly support continuing demand. Retention is assessed from aggregate operating evidence; no patient retention rate or demonstrated resistance to price increases is available.
margin resilience · 2/4 · Product revenues grew faster than product costs from 2024 to 2025 and operating cash generation strengthened. However, earnings varied substantially with R&D spending, impairment and settlement effects. These results support mixed economic resilience without proving a pricing-driven margin advantage.
contractual freedom · 1/4 · Government-controlled prices, country-specific reimbursement negotiations and mandatory discounts materially constrain price and access terms. Freedom is limited rather than wholly absent.
Predictability93
Five consecutive annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.
- Nondeclining revenue years (%)
- 100.00
- Revenue growth volatility (pp)
- 4.40
- Positive FCF years (%)
- 100.00
- FCF margin volatility (pp)
- 7.95
Financial strength—
Missing required inputs: debtFcfGrade, netDebtEbitGrade. Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, or reported pretax profit plus reported interest expense when operating income is unavailable. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.
- interestCoverageGrade
- 100.00
- currentRatioGrade
- 100.00
- Interest coverage (x)
- 623.91
- Current ratio (x)
- 3.32
Capital allocation—
Missing required inputs: operatingReturn. Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income or, if unavailable, EBIT calculated from reported pretax profit plus reported interest expense; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. Nonpositive invested capital has no defined return and remains unavailable. Does not establish acquisition quality or buyback timing.
- 3-year average dilution (%)
- -4.13
- 3-year average SBC / revenue (%)
- 5.65
- cashConversionGrade
- 100.00
Management69
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
capital discipline · 2/4 · Positive operating cash flow across 2023–2025 and increased June 2026 liquidity support funding capacity. Against that, the $2.005 billion 2024 repurchase, substantial R&D spending, impairment, stock compensation and subsequent share-count increase leave allocation outcomes mixed. Repurchase value creation is not established.
incentive alignment · 3/4 · Actual 2025 awards include a substantial CEO performance-share allocation and granted awards tied to three-year relative TSR. Multiyear vesting, ownership guidelines and double-trigger provisions support alignment. These are disclosed arrangements, not assumed adoption of meeting proposals; actual ownership compliance and ultimate payouts remain missing.
execution · 3/4 · Multiyear product and royalty growth, received development and regulatory milestones, and strong 2025 operating cash generation demonstrate commercial and development execution. This assessment partly uses aggregate operating outcomes and does not attribute all results to the CEO who joined in 2025 or treat pipeline forecasts as achievements.
governance · 3/4 · Disclosed independent committees, annual director elections, majority voting, proxy access and auditor meetings without management support strong formal governance. The inducement plan used a permitted stockholder-approval exception. Policies establish structure, not exceptional oversight effectiveness or subsequent voting outcomes.
Evidence
Our portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products JAKAFI® (ruxolitinib), ICLUSIG® (ponatinib), PEMAZYRE® (pemigatinib), OPZELURA® (ruxolitinib cream), MINJUVI® (tafasitamab), MONJUVI® (tafasitamab-cxix), ZYNYZ® (retifanlimab-dlwr), as well as NIKTIMVO™ (axatilimab-csfr), which is co-commercialized.
Note 1: commercialized product portfolio · Filed 10/02/2026
(“MacroGenics”). Under this agreement, we received exclusive development and commercialization rights worldwide to MacroGenics’ INCMGA0012 (formerly MGA012), an investigational monoclonal antibody that inhibits PD-1.
MacroGenics collaboration: exclusive worldwide development and commercialization rights · Filed 28/07/2026
114 Table of Contents Net income for our segment was as follows (in thousands): Year Ended December 31, 2025 2024 2023 Product revenues, net $ 4,354,333 $ 3,618,888 $ 3,165,168 Product royalty revenues 636,909 579,329 523,481 Milestone and contract revenues 150,000 43,000 7,000 Total revenues 5,141,242 4,241,217 3,695,649 Costs, expenses and other: Cost of product revenues (including definite-lived intangible amortization) 372,130 312,068 254,990 Contract dispute settlement (242,251) — — Research and development - internal1 984,730 957,043 815,025 Research and development - external2 967,848 866,005 775,919 Other research and development3 97,574 783,800 36,650 Sales and marketing 1,094,754 945,428 876,703 General and administrative 281,452 296,729 278,959 Asset impairment 76,275 — 5,631 (Gain) loss on change in fair value of acquisition-related contingent consideration (6,129) 19,803 29,202 (Profit) and loss sharing under collaboration agreements — (1,025) 2,045 Other segment items4 228,209 28,751 22,926 Net income $ 1,286,650 $ 32,615 $ 597,599 1.Research and development - internal is comprised of internally generated costs such as salaries, travel, regulatory costs, lab costs, contracting, etc.
Segment results: 2023–2025 revenues, expenses and net income · Filed 10/02/2026
Since the inception of the agreement through June 30, 2026, we recognized and received, in aggregate, $149.0 million for the achievement of development milestones, $335.0 million for the achievement of regulatory milestones, $50.0 million for the achievement of sales milestones, and $100.0 million for the functional intellectual property transfer related to Type 1 diabetes mellitus.
Collaboration disclosures: milestones and intellectual-property transfer payments received through June 30, 2026 · Filed 28/07/2026
Product royalty revenue related to Lilly net sales of OLUMIANT outside of the United States for the three and six months ended June 30, 2026 was $38.5 million and $74.9 million, respectively.
Lilly collaboration: OLUMIANT royalties for the three and six months ended June 30, 2026 · Filed 28/07/2026
Product royalty revenue related to Lilly net sales of OLUMIANT outside of the United States for the three and six months ended June 30, 2025 was $33.5 million and $64.3 million, respectively.
Lilly collaboration: comparable OLUMIANT royalties for 2025 · Filed 28/07/2026
During the year ended December 31, 2025, our milestone and contract revenues were derived from a combination of upfront payments received from our third party collaborators for the transfer of functional intellectual property, primarily the $100.0 million payment received from Lilly in the fourth quarter of 2025, as well as developmental milestones received from our third party collaborators.
Revenue discussion: 2025 intellectual-property transfer and developmental milestone payments · Filed 10/02/2026
Our means of protecting our proprietary rights may not be adequate, and our competitors may: •independently develop substantially equivalent proprietary information, products and techniques; •otherwise gain access to our proprietary information; or •design around patents issued to us or our other intellectual property.
Intellectual-property risk: equivalent development and patent circumvention · Filed 28/07/2026
If we do not control the intellectual property rights in-licensed to us with respect to a drug candidate and the entity that controls such intellectual property rights does not adequately protect those rights, our rights may be impaired, which may impact our ability to develop, market and commercialize the in-licensed drug candidate.
Intellectual-property risk: protection of in-licensed rights · Filed 28/07/2026
We derive a substantial portion of our total revenues from product royalties and milestone payments under our collaboration agreements, with royalties on JAKAVI and OLUMIANT representing most of our product royalty, milestone and contract revenues in each of the three most recently completed fiscal years.
Collaboration risk: concentration of royalties and milestone revenues · Filed 28/07/2026
The following table provides a summary of activity with respect to our sales allowances and accruals (in thousands): Six Months Ended June 30, 2026 Discounts and Distribution Fees Commercial & Government Rebates and Chargebacks Co-Pay Assistance and Other Discounts Product Returns Total Balance at January 1, 2026 $ 38,780 $ 562,167 $ 14,189 $ 30,955 $ 646,091 Allowances for current period sales 116,119 1,058,348 107,748 7,116 1,289,331 Allowances for prior period sales (3,575) (222,619) (28) (3) (226,225) Credits/payments for current period sales (73,712) (737,743) (93,926) (15) (905,396) Credits/payments for prior period sales (35,203) (214,767) (14,161) (5,915) (270,046) Balance at June 30, 2026 $ 42,409 $ 445,386 $ 13,822 $ 32,138 $ 533,755 U.S.
Sales allowances: six months ended June 30, 2026 · Filed 28/07/2026
In many markets outside of the United States, including countries of the European Union (EU), drug pricing and reimbursement are subject to government control, and government authorities are making greater efforts to limit or regulate the price of drug products.
Pricing and reimbursement: government control outside the United States · Filed 10/02/2026
We are at a pivotal moment: advancing a deep pipeline, expanding our global footprint, and preparing for a future that extends beyond a loss of exclusivity.
Compensation discussion: preparation for loss of exclusivity · Filed 28/04/2026
77 Table of Contents INCYTE CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Year Ended December 31, 2025 2024 2023 Cash flows from operating activities: Net income $ 1,286,650 $ 32,615 $ 597,599 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 93,286 89,248 82,660 Stock-based compensation 249,346 266,058 215,889 Deferred income taxes 247,685 (85,553) (158,898) Other, net 14,857 (9,053) 16,948 (Gain) on equity investments (21,310) (116,025) (43,893) (Gain) loss on change in fair value of acquisition-related contingent consideration (6,129) 19,803 29,202 Asset impairment 76,275 — 5,631 Changes in operating assets and liabilities: Accounts receivable (170,772) (111,586) (98,678) Prepaid expenses and other assets (156,237) 10,365 (42,491) Inventory (58,513) (127,633) (170,151) Accounts payable 6,562 88,159 (167,945) Accrued and other liabilities (148,202) 278,939 230,614 Net cash provided by operating activities 1,413,498 335,337 496,487 Cash flows from investing activities: Purchase of long term investments (7,875) — (10,000) Sale of equity investments 8 284,781 45 Capital expenditures (58,867) (86,263) (32,486) Payments for intangible assets (25,000) (13,900) (15,000) Purchases of marketable securities (295,507) (258,370) (456,020) Maturities of marketable securities 284,631 231,269 305,784 Net cash (used in) provided by investing activities (102,610) 157,517 (207,677) Cash flows from financing activities: Repurchase of Common Stock — (2,004,790) — Excise tax paid on repurchase of Common Stock (19,100) — — Proceeds from issuance of Common Stock under stock plans 221,762 49,301 35,836 Tax withholdings related to restricted and performance share vesting (76,818) (40,302) (28,550) Payment of finance lease liabilities (4,544) (3,798) (3,360) Payment of contingent consideration (20,261) (21,958) (23,959) Net cash provided by (used in) financing activities 101,039 (2,021,547) (20,033) Effect of exchange rates on cash, cash equivalents, and restricted cash (1,709) 2,923 (6,676) Net increase (decrease) in cash, cash equivalents, and restricted cash 1,410,218 (1,525,770) 262,101 Cash, cash equivalents, and restricted cash at beginning of period 1,689,451 3,215,221 2,953,120 Cash, cash equivalents, and restricted cash at end of period $ 3,099,669 $ 1,689,451 $ 3,215,221 Supplemental Schedule of Cash Flow Information Cash paid for contract dispute settlement $ 294,881 $ — $ — Unpaid purchases of property and equipment $ 4,929 $ 2,597 $ 5,052 Unpaid excise tax on repurchase of common stock $ — $ 19,185 $ — Leased assets obtained in exchange for new operating lease liabilities $ 3,163 $ 9,674 $ 5,275 Leased assets obtained in exchange for new finance lease liabilities $ 937 $ 8,906 $ 2,257 See accompanying notes.
Consolidated cash flows: 2023–2025 operations, investments, repurchases and stock compensation · Filed 10/02/2026
Financial Statements INCYTE CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except number of shares and par value) June 30, 2026 December 31, 2025* (unaudited) ASSETS Current assets: Cash and cash equivalents $ 3,982,375 $ 3,097,817 Marketable securities—available-for-sale (amortized cost $555,856 and $480,793 as of June 30, 2026 and December 31, 2025, respectively; allowance for credit losses $0 as of June 30, 2026 and December 31, 2025) 553,365 482,787 Accounts receivable 1,125,203 1,024,407 Inventory 112,542 101,060 Prepaid expenses and other current assets 253,087 317,831 Total current assets 6,026,572 5,023,902 Restricted cash 1,816 1,852 Long term equity investments 104,387 47,991 Inventory 345,026 342,232 Property and equipment, net 709,469 730,885 Finance lease right-of-use assets, net 25,559 27,520 Other intangible assets, net 103,196 117,131 Goodwill 133,000 133,000 Deferred income tax asset 336,863 515,294 Other assets, net 86,759 18,166 Total assets $ 7,872,647 $ 6,957,973 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 250,401 $ 209,938 Accrued compensation 148,319 228,071 Accrued and other current liabilities 870,306 1,031,501 Finance lease liabilities 4,259 4,516 Acquisition-related contingent consideration 38,811 41,144 Total current liabilities 1,312,096 1,515,170 Acquisition-related contingent consideration 63,189 79,856 Finance lease liabilities 28,420 30,199 Other liabilities 124,515 165,270 Total liabilities 1,528,220 1,790,495 Commitments and contingencies (Note 15) Stockholders’ equity: Preferred Stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding — — Common Stock, $0.001 par value; 400,000,000 shares authorized; 200,977,687 and 198,460,009 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively 201 198 Additional paid-in capital 5,221,804 4,928,049 Accumulated other comprehensive income 19,718 25,462 Retained earnings 1,102,704 213,769 Total stockholders’ equity 6,344,427 5,167,478 Total liabilities and stockholders’ equity $ 7,872,647 $ 6,957,973 *The condensed consolidated balance sheet at December 31, 2025 has been derived from the audited consolidated financial statements at that date.
June 30, 2026 balance sheet: liquidity, liabilities and outstanding shares · Filed 28/07/2026
Sales from our core business (excluding Jakafi) reached $1.26 billion, representing a 53% increase compared to 2024.
CEO shareholder letter: reported 2025 sales excluding Jakafi · Filed 28/04/2026
Looking ahead, this core business has the potential to grow at a 15-20% CAGR over the next five years, reaching $3–$4 billion by 2030.
CEO shareholder letter: prospective core-business growth · Filed 28/04/2026
At present, we are advancing seven high‑value assets with the potential to generate over $10 billion in non-risk adjusted sales.
CEO shareholder letter: non-risk-adjusted pipeline sales potential · Filed 28/04/2026
26 Proxy Statement 2026 Proposal 2 Advisory Vote to Approve Executive Compensation (2)Performance shares comprised 60% of our CEOs’ target equity award values for 2025.
Executive compensation: 2025 CEO performance-share target allocation · Filed 28/04/2026
The Management Equity Award Committee determined that the performance share awards granted in July 2025 are based solely on our relative total shareholder return (“TSR”) performance compared to the TSR of companies in a fixed peer group comprised of 43 Nasdaq Biotechnology Index (“NBI”) and other non-U.S.-traded biopharmaceutical companies with market capitalizations generally between $4 billion and $100 billion as of January 1, 2025, the beginning of the three-year performance period.
Executive compensation: July 2025 performance awards and three-year relative TSR condition · Filed 28/04/2026
These percentages remain unchanged for 2026 Our Compensation Committee uses an independent compensation consultant and considers peer groups in establishing executive compensation Performance shares have a three-year performance period Robust anti-hedging and anti-speculation policies in place Robust stock ownership guidelines for our CEO, executive officers and our directors Our Compensation Committee comprises all independent directors Double-trigger equity vesting in the event of a change-in-control We conduct an annual say-on-pay vote Stock options and RSU awards have a minimum vesting period of 12 months with a vesting period over 4 years We engage proactively with our shareholders throughout the year We routinely review our peer group to provide perspective on competitive pay levels We require executives to plan any stock trading in advance through the use of 10b5-1 plans What We Don’t Do We do not reprice stock options We do not provide golden parachute excise tax gross-ups We do not provide single-trigger equity vesting in the event of a change-in-control We do not provide excessive perquisites for executives 24 Proxy Statement 2026 Proposal 2 Advisory Vote to Approve Executive Compensation Compensation Program Strategy, Objectives and Design At Incyte, our compensation philosophy is designed to support both where we are as a company today and our future direction.
Compensation practices: vesting, ownership guidelines and change-in-control provisions · Filed 28/04/2026
Proxy Statement 2026 15 Proposal 1 Election of Directors Corporate Governance What We Do Majority voting for directors in uncontested elections Audit and Finance Committee receives semiannual compliance updates Strong and active Board Chair, representing one of our largest shareholders Board members have complete access to management and employees in their discretion and Board committees may seek advice from outside advisors Audit and Finance Committee, Nominating and Corporate Governance Committee and Compensation Committee comprised solely of independent directors Pre-clearance by our General Counsel required for trading in our stock by any director, and all executive trading must be through a pre-cleared trading plan Audit and Finance Committee regularly meets with Ernst & Young LLP, our independent registered public accounting firm, as well as our corporate audit services team – without members of executive management present Maintain robust ethics requirements through our Code of Business Conduct and Ethics, Senior Financial Officers’ Code of Ethics and Board of Directors Code of Conduct and Ethics An independent compensation consultant is engaged by and reports directly to our Compensation Committee Board review and approval of corporate strategic plan, including the budget, at least annually Annual election of all directors High Board and committee attendance Limits on outside board and audit committee service Extensive ongoing shareholder outreach Proxy access bylaw (3% ownership, 3 years, nominees up to 20% of the Board) Audit and Finance Committee receives updates from our cybersecurity team at least twice per year What We Don’t Do No staggered or classified Board No hedging or speculative trading in our stock by directors, executives or other employees No plurality voting in uncontested Board elections Board members may not be “overboarded” Majority Voting Policy Our Bylaws provide that, in an uncontested election, director nominees must receive a majority of the votes cast to be elected to the Board.
Corporate governance: independent committees, annual elections and shareholder rights · Filed 28/04/2026
In reliance on Nasdaq Marketplace Rule 5635(c)(4), stockholder approval was not obtained.
2024 Inducement Plan: stockholder approval exception · Filed 28/07/2026
Reimbursement in the EU must be negotiated on a country-by-country basis and in many countries a drug product cannot be commercially launched until reimbursement is approved.
EU reimbursement: country-specific negotiation and launch restrictions · Filed 10/02/2026
Our net sales may fluctuate from quarter to quarter due to our customers’ purchasing patterns over the course of the year, including as a result of increased inventory building by customers in advance of expected or announced price increases.
Net sales discussion: purchasing patterns and inventory building around price increases · Filed 28/07/2026
Net sales are recorded net of estimated product returns, pricing discounts including rebates offered pursuant to mandatory federal and state government programs and chargebacks, prompt pay discounts and distribution fees and co-pay assistance.
Net sales recognition: rebates, discounts, chargebacks and assistance · Filed 28/07/2026
